LXRX Lexicon Pharmaceuticals
- 1.940
- +0.020+1.04%
- 1.920
- -0.020-1.02%
Lexicon Pharmaceuticals News
Lexicon Pharmaceuticals Says Post Hoc Analysis of Infepa Trial Showed Decreased Heart Failure Risk
Lexicon Pharmaceuticals (LXRX) said Tuesday that a post hoc analysis of clinical data from a phase 3 study showed that its diabetes and kidney disease treatment Inpefa reduced the risk of heart failure events in certain patients.
New Post-Hoc Analysis of Pooled Phase 3 Data Shows That INPEFA (Sotagliflozin) Reduced Risk of Heart Failure Events in Patients With Preserved Ejection Fraction
Analysis adds to the body of evidence differentiating INPEFA as a dual oral inhibitor of SGLT2 and SGLT1THE WOODLANDS, Texas, May 14, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq:
Lexicon Pharmaceuticals to Participate in the Bank of America Securities Healthcare Conference 2024
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q1 2024 Earnings Call Transcript
Earnings Call Summary | Lexicon Pharmaceuticals(LXRX.US) Q1 2024 Earnings Conference
The following is a summary of the Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2024 Earnings Call Transcript:Financial Performance:Lexicon Pharmaceuticals raised $250 million in an oversubscribed offering
Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2024 Earnings Call Transcript
Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2024 Earnings Call Transcript
Analysts Are Bullish on These Healthcare Stocks: Cigna (CI), Lexicon Pharmaceuticals (LXRX)
Optimistic Buy Rating for Lexicon Pharmaceuticals Amid Strong Inpefa Sales Outlook and Efficient Financial Management
Needham Keeps Their Hold Rating on Lexicon Pharmaceuticals (LXRX)
Lexicon Pharmaceuticals Inc (LXRX) Q1 2024 Earnings Call Transcript Highlights: Navigating ...
Lexicon Pharmaceuticals Reports Q1 2024 Earnings: Aligns With EPS Projections Amidst Strategic ...
Earnings Flash (LXRX) LEXICON PHARMACEUTICALS Posts Q1 Revenue $1.1M, Vs. Street Est of $1.4M
04:27 PM EDT, 05/02/2024 (MT Newswires) -- Earnings Flash (LXRX) LEXICON PHARMACEUTICALS Posts Q1 Revenue $1.1M, vs. Street Est of $1.4M
Press Release: Lexicon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
Lexicon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update Commercial launch of INPEFA(R) (sotagliflozin) for Heart Failure continues to progress Resubmission
Lexicon Pharma 1Q Rev $1.13M >LXRX
Lexicon Pharma 1Q Rev $1.13M >LXRX
Lexicon Pharma Initiated at Outperform by Leerink Partners
Lexicon Pharma Initiated at Outperform by Leerink Partners
Lexicon Pharmaceuticals (LXRX.US) was first covered by Leerink Partners, which gave it an superior market rating and a target price of $5.00.
Lexicon Pharmaceuticals (LXRX.US) was first covered by Leerink Partners, which gave it an superior market rating and a target price of $5.00.
Leerink Partners Starts Lexicon Pharmaceuticals With Outperform Rating, $5 Price Target
Leerink Partners Starts Lexicon Pharmaceuticals With Outperform Rating, $5 Price Target.
Lexicon Pharmaceuticals: A Buy Rating on Strong Market Prospects and Innovative Pipeline
Press Release: Lonnel Coats Retires as Chief Executive Officer and Board Member of Lexicon Pharmaceuticals
Lonnel Coats Retires as Chief Executive Officer and Board Member of Lexicon Pharmaceuticals THE WOODLANDS, Texas, April 29, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today
Lexicon Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 2, 2024
THE WOODLANDS, Texas, April 29, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) will release its first quarter 2024 financial results on Thursday, May 2, 2024 after the markets close. Management
Analysis
Price Target
No Data
